Following the advice of a nearly unanimous joint FDA advisory committee, the agency decided that clozapine's REMS program is no longer necessary to ensure that the benefits of the drug outweigh ...
By Ellen Barry The Food and Drug Administration has taken a crucial step toward expanding access to the antipsychotic medication clozapine, the only drug approved for treatment-resistant ...
(HealthDay News) — The U.S. Food and Drug Administration has removed one hurdle faced by patients with schizophrenia when filling prescriptions for the antipsychotic medication clozapine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback